ASRT Stock Recent News

The Supreme Court recently nullified the Biden administration's proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, this program intended to forgive nearly $430 billion in loans.

Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading product, Indocin, has seen increased sales and a recent 5x market expansion not yet included in company guidance. Assertio ranks in the top 1% of stocks in both value and high-quality momentum.

Share portion of takeover by Assertio Holdings covers the value of the shares plus a merger spread. Contingent value rights on their drug are also included, adding up to $0.20 per share. CVR payout will require aggressive sales growth, but they're effectively free.

Assertio Holdings, a pharmaceutical company, has demonstrated solid financials and growth potential, with a focus on reducing debt levels and increasing cash generation through strategic acquisitions. The company's liquidity position has improved over the past few years, with increasing current and cash ratios indicating a well-managed leverage condition. Despite potential risks such as increasing competition from generics and supply chain vulnerabilities, Assertio's strong financial structures and progress make it a suitable buy-rated stock.

In Q1 FY2023, Assertio achieved significant progress in executing the new strategy brought on board by CEO Dan Peisert. The market expects ASRT's EPS to decline nearly 82% YoY in FY2023, but then rebound strongly, with a compound annual growth rate [CAGR] of 23.7% over the next 3 years. I reiterate my previous "Buy" rating and set a 12-month price target of $10.16 per share, implying an upside potential of 60% over the medium term.

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2023 Results Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President and Chief Executive Officer Paul Schwichtenberg - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - ROTH Capital William Wood - B. Riley Securities Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti & Company Operator Good afternoon and welcome to the Assertio Holdings, Inc. First Quarter 2023 Financial Results Conference Call.

The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of prediction before.

Assertio Holdings stock has fallen 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95% over the same period. The SPPI deal is expected to give Assertio access to Rolvedon and be accretive to adjusted EPS and operating cash flow in FY2024.

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning.  The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.